Thromboelastometry and Ischemic Stroke (ThromboPredict)

Sponsor
University Hospital, Caen (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04870684
Collaborator
(none)
200
1
36
5.6

Study Details

Study Description

Brief Summary

In ischemic stroke, the recanalization rate after intravenous thrombolysis has been estimated to be less than 50% in patients with proximal intracranial artery occlusion; this rate is greater than 80% after endovascular thrombectomy. Thromboelastometry is a method of analysis of coagulation and fibrinolysis in whole blood. The main objective of this study is to evaluate whether the parameters obtained by thromboelastometry are predictive of revascularization at arteriography during mechanical thrombectomy, after treatment with rt-PA thrombolysis.

Condition or Disease Intervention/Treatment Phase
  • Other: thromboelastometry test

Detailed Description

This is a single-center prospective observational study at the University Hospital of Caen. Any patient presenting a neurological deficit of sudden onset, compatible with a ischemic stroke diagnosed on brain imaging and eligible for thrombolysis by rtPA and/or a endovascular thrombectomy procedure will be included. Clot formation kinetics will be assessed by thromboelastometry (ROTEM® and/or QUANTRA®) to determine the predictive parameters of revascularization. The parameters of clot formation and lysis as well as revascularization according to thrombo-inflammation processes will be studied.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Interest of Thromboelastometry as a Biomarker of Post-thrombolysis or Post-thrombectemia Revascularization Success in Ischemic Stroke: a Prospective, Single-center, Observational Study in an Emergency Department
Anticipated Study Start Date :
May 1, 2021
Anticipated Primary Completion Date :
Apr 30, 2024
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
sucess of revascularization

group of patients for whom after thrombolysis neurological improvement will be observed and recanalization on imaging will be seen.

Other: thromboelastometry test
This study does not modify the usual care of the patient. Only 5 citrated tubes (maximum 15 mL of blood) are collected in addition to the initial emergency department sample (routine care). The patient's care follows the classic thrombolysis alert pathway. There is no additional complementary examination or additional neurological evaluation. Clot formation kinetics will be evaluated by thromboelastometry to determine the predictive parameters of revascularization. Clot formation and lysis parameters as well as revascularization according to thrombo-inflammation processes will be studied.

Outcome Measures

Primary Outcome Measures

  1. Prediction of the success of the revascularization procedure by thromboelastometry [One hour after the blood test]

    All the parameters of clot formation and lysis will be studied, in particular the area under the curve (AUC)

  2. Does clot firmness could predict the success of the revascularization [One hour after the blood test]

    clot firmness (MCF in millimeter, mm)

  3. Prediction of the success of the revascularization procedure by thromboelastometry [One hour after the blood test]

    clot lysis time (seconde).

Secondary Outcome Measures

  1. Thomboelastometry and prediction of thrombolysis + thrombectomy efficacy [during thrombectomy procedure]

    effectiveness of thrombectomy will be assessed per-arteriogram by the TICI score (Grade 0: no perfusion Grade 1: penetration with minimal perfusion Grade 2: partial perfusion Grade 2A: only partial filling (less than two-thirds) of the entire vascular territory is visualized Grade 2B: complete filling of all of the expected vascular territory is visualized but the filling is slower than normal Grade 3: complete perfusion)

  2. Thomboelastometry and prediction of thrombectomy efficacy [immediatly after thrombectomy procedure]

    number of passes required for successful recanalization thrombolysis

  3. Thomboelastometry and prediction of thrombectomy efficacy [through study completion, an average of 3 years]

    puncture to recanalization (minute)

  4. Thomboelastometry and prediction of success of recanalization by thrombectomy alone [just at the end of thrombectomy procedure]

    Effectiveness of thrombectomy will be assessed by the TICI score ((Grade 0: no perfusion Grade 1: penetration with minimal perfusion Grade 2: partial perfusion Grade 2A: only partial filling (less than two-thirds) of the entire vascular territory is visualized Grade 2B: complete filling of all of the expected vascular territory is visualized but the filling is slower than normal Grade 3: complete perfusion)

  5. Prediction of success of thrombolysis ["Day 1", "Day 3" after thrombolysis]

    presence or absence of a clot on MRI or angioscan

  6. Thomboelastometry and prediction of neurological outcome ["D0", "Day 1", "Day 3" after revascularization]

    The use of the NIHSS score will allow the neurological evaluation of the patient (at admission and 24h/72h after the recanalization attempt). Neurological outcome, as assessed by the NIHSS score, is considered favorable if the NIHSS score at 24h/72h post-recanalization is equal to 0 or 1 or if there is an improvement in the NIHSS score of at least four points between the admission score and the score at 24h/72h post-recanalization.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age > 18 years

  • Diagnosis of ischemic stroke

  • Decision of intravenous thrombolysis and/or endovascular thrombectomy by the neurologist and/or interventional neuroradiologist.

  • Patient admitted to the emergency department during the hours and days when the hematology-biology laboratory is open (Monday to Friday from 8:30 a.m. to 6:30 p.m.)

  • No opposition to the research from the patient or his relatives

  • Inclusions according to the emergency procedure

Exclusion Criteria:
  • Age < 18 ans

  • Formal contraindication to thrombolysis and/or endovascular thrombectomy, disorders of hemostasis and anticoagulant treatment.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University hospital of Caen, emergency department Caen France 14000

Sponsors and Collaborators

  • University Hospital, Caen

Investigators

  • Principal Investigator: Richard Macrez, Doctor, University hospital of Caen and faculty of medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Caen
ClinicalTrials.gov Identifier:
NCT04870684
Other Study ID Numbers:
  • 2021-A00171-40
First Posted:
May 3, 2021
Last Update Posted:
May 3, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Caen
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 3, 2021